Evotec SE
XETRA EVT.DE
Evotec SE Operating Cash Flow for the year ending December 31, 2023: USD 40.22 M
-
Evotec SE Operating Cash Flow for the year ending December 31, 2022 was USD 217.31 M, a 56.17% change year over year.
-
Evotec SE Operating Cash Flow for the year ending December 31, 2021 was USD 139.15 M, a 154.71% change year over year.
-
Evotec SE Operating Cash Flow for the year ending December 31, 2020 was USD 54.63 M, a 15.31% change year over year.
-
Evotec SE Operating Cash Flow for the year ending December 31, 2019 was USD 47.38 M, a -73.51% change year over year.
| Date | Operating Cash Flow | Net Cash Used For Investing Activities | Net Cash Used Provided By Financing Activities | Dividends Paid |
|---|
| CEO | Dr. Christian Wojczewski |
| IPO Date | Nov. 12, 1999 |
| Location | Germany |
| Headquarters | Essener Bogen 7 |
| Employees | 5,007 |
| Sector | Health Care |
| Industries | |
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
Past 5 years
USD 30.51
USD 46.27
StockViz Staff
January 15, 2025
Any question? Send us an email